JP2022051744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022051744A5 JP2022051744A5 JP2022001433A JP2022001433A JP2022051744A5 JP 2022051744 A5 JP2022051744 A5 JP 2022051744A5 JP 2022001433 A JP2022001433 A JP 2022001433A JP 2022001433 A JP2022001433 A JP 2022001433A JP 2022051744 A5 JP2022051744 A5 JP 2022051744A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- seq
- antigen receptor
- chimeric antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 16
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088423P | 2014-12-05 | 2014-12-05 | |
| US62/088,423 | 2014-12-05 | ||
| JP2017529682A JP7098325B2 (ja) | 2014-12-05 | 2015-12-07 | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| PCT/US2015/064303 WO2016090369A1 (en) | 2014-12-05 | 2015-12-07 | Cs1 targeted chimeric antigen receptor-modified t cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529682A Division JP7098325B2 (ja) | 2014-12-05 | 2015-12-07 | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022051744A JP2022051744A (ja) | 2022-04-01 |
| JP2022051744A5 true JP2022051744A5 (enExample) | 2022-07-12 |
| JP7252379B2 JP7252379B2 (ja) | 2023-04-04 |
Family
ID=55069093
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529682A Active JP7098325B2 (ja) | 2014-12-05 | 2015-12-07 | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| JP2022001433A Active JP7252379B2 (ja) | 2014-12-05 | 2022-01-07 | Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529682A Active JP7098325B2 (ja) | 2014-12-05 | 2015-12-07 | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10821161B2 (enExample) |
| EP (2) | EP3227315B1 (enExample) |
| JP (2) | JP7098325B2 (enExample) |
| KR (1) | KR102558502B1 (enExample) |
| CN (2) | CN107429253B (enExample) |
| AU (2) | AU2015357485B2 (enExample) |
| BR (1) | BR112017011893A2 (enExample) |
| CA (1) | CA2969704C (enExample) |
| IL (3) | IL290459B2 (enExample) |
| MX (2) | MX384964B (enExample) |
| RU (1) | RU2727451C2 (enExample) |
| WO (1) | WO2016090369A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100615A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| AU2015249554B2 (en) | 2014-04-23 | 2021-08-19 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| AU2015357485B2 (en) | 2014-12-05 | 2020-10-15 | City Of Hope | CS1 targeted chimeric antigen receptor-modified T cells |
| AU2016212158B2 (en) | 2015-01-26 | 2021-06-03 | Allogene Therapeutics, Inc. | mAb-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells |
| ES2848478T3 (es) | 2015-09-11 | 2021-08-09 | Biosceptre Uk Ltd | Receptores quiméricos para antígenos y usos de estos |
| EP3408297A2 (en) | 2016-01-29 | 2018-12-05 | Med Manor Organics, (P) Ltd | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
| US10603380B2 (en) | 2016-04-01 | 2020-03-31 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
| TWI761831B (zh) | 2016-04-01 | 2022-04-21 | 美商凱特製藥公司 | 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途 |
| DK3436030T3 (da) | 2016-04-01 | 2022-11-21 | Kite Pharma Inc | Kimæriske receptorer og fremgangsmåder til anvendelse deraf |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| CA3026858A1 (en) | 2016-06-30 | 2018-01-04 | F. Hoffmann-La Roche Ag | Improved adoptive t-cell therapy |
| CN105949324B (zh) * | 2016-06-30 | 2019-08-27 | 上海恒润达生生物科技有限公司 | 靶向gpc3的嵌合抗原受体及其用途 |
| WO2018064626A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Adaptive chimeric antigen receptor t-cell design |
| US12083148B2 (en) | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| EP3600352A1 (en) * | 2017-03-20 | 2020-02-05 | City of Hope | Cs1 targeted chimeric antigen receptor-modified t cells for treatment of al amyloidosis |
| PE20200152A1 (es) | 2017-03-27 | 2020-01-17 | Hoffmann La Roche | Receptores de union a antigeno mejorados |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| EP3615059B1 (en) | 2017-04-28 | 2025-11-19 | Julius-Maximilians-Universität Würzburg | Ror1-specific chimeric antigen receptors (car) with humanized targeting domains |
| CA3071303A1 (en) * | 2017-08-01 | 2019-02-07 | Julius-Maximilians-Universitat Wurzburg | Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia |
| WO2019032972A1 (en) | 2017-08-11 | 2019-02-14 | Idac Holdings, Inc. | TRAFFIC ORIENTATION AND SWITCHING BETWEEN MULTIPLE ACCESS NETWORKS |
| PL3704230T3 (pl) * | 2017-11-01 | 2025-02-24 | Juno Therapeutics, Inc. | Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie |
| JP7285267B2 (ja) * | 2017-11-14 | 2023-06-01 | アーセルクス インコーポレイテッド | Ｄドメイン含有ポリペプチドおよびその使用 |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| EP3710471A1 (en) | 2017-11-16 | 2020-09-23 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| SG11202007513PA (en) | 2018-02-16 | 2020-09-29 | Kite Pharma Inc | Modified pluripotent stem cells and methods of making and use |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| US20220089718A1 (en) * | 2018-05-21 | 2022-03-24 | Biosceptre (Uk) Limited | Chimeric antigen receptors with modified linker domains and uses thereof |
| US11951131B2 (en) | 2018-07-03 | 2024-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SLAMF7 chimeric antigen receptors |
| US12281152B2 (en) | 2018-08-01 | 2025-04-22 | City Of Hope | TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors |
| WO2020025039A1 (zh) * | 2018-08-03 | 2020-02-06 | 南京驯鹿医疗技术有限公司 | 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用 |
| CN113412117B (zh) | 2018-12-12 | 2025-03-04 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| IL299249B2 (en) | 2019-04-03 | 2024-01-01 | Prec Biosciences Inc | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
| EP4549555A3 (en) * | 2019-05-24 | 2025-07-30 | City of Hope | Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies |
| CN114222763A (zh) * | 2019-06-19 | 2022-03-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点 |
| CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
| KR20230010228A (ko) * | 2020-05-08 | 2023-01-18 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars) |
| WO2021242719A1 (en) * | 2020-05-27 | 2021-12-02 | The Medical College Of Wisconsin, Inc. | Improved lentiviral vector transfer plasmid and methods of use |
| WO2022031602A1 (en) * | 2020-08-06 | 2022-02-10 | Promab Biotechnologies, Inc. | Cs1- antibody and anti-cs1-car-t cells |
| JP7776493B2 (ja) * | 2020-08-10 | 2025-11-26 | ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク | シグレック６結合ポリペプチド |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| WO2022206941A1 (zh) * | 2021-04-02 | 2022-10-06 | 克莱格医学有限公司 | Cs1工程化细胞及其组合物 |
| US20250032543A1 (en) * | 2021-12-06 | 2025-01-30 | The Children's Hospital Of Philadelphia | Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices) |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| WO2023180511A1 (en) * | 2022-03-25 | 2023-09-28 | F. Hoffmann-La Roche Ag | Improved chimeric receptors |
| WO2024114691A1 (en) * | 2022-12-02 | 2024-06-06 | Guangzhou Litai Biotechnology Co., Ltd. | Human cs1 car-t cells |
| CN119019554B (zh) * | 2023-05-25 | 2025-08-12 | 东莞市朋志生物科技有限公司 | 抗白介素6抗体、检测白介素6的试剂和试剂盒 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3267966B2 (ja) | 1989-08-11 | 2002-03-25 | アムラド・コーポレイション・リミテッド | 顆粒球―マクロファージコロニー刺激因子受容体およびその誘導体における改良 |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| EP2520588A1 (en) | 2005-08-19 | 2012-11-07 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007047829A2 (en) | 2005-10-19 | 2007-04-26 | Laboratoires Serono S.A. | Novel heterodimeric proteins and uses thereof |
| GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| AU2011215685B2 (en) | 2010-02-12 | 2015-08-20 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CA3116051C (en) | 2012-03-23 | 2023-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| WO2013151762A1 (en) | 2012-04-05 | 2013-10-10 | Ac Immune S.A. | Humanized tau antibody |
| AU2014259675B2 (en) * | 2013-05-03 | 2019-05-02 | Ohio State Innovation Foundation | CS1-specific chimeric antigen receptor engineered immune effector cells |
| ES2767423T3 (es) * | 2014-01-13 | 2020-06-17 | Hope City | Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso |
| EP3105317B1 (en) | 2014-02-14 | 2018-09-19 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US20170051037A1 (en) | 2014-05-02 | 2017-02-23 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
| AU2015357485B2 (en) | 2014-12-05 | 2020-10-15 | City Of Hope | CS1 targeted chimeric antigen receptor-modified T cells |
| EP3600352A1 (en) * | 2017-03-20 | 2020-02-05 | City of Hope | Cs1 targeted chimeric antigen receptor-modified t cells for treatment of al amyloidosis |
-
2015
- 2015-12-07 AU AU2015357485A patent/AU2015357485B2/en not_active Ceased
- 2015-12-07 US US15/533,153 patent/US10821161B2/en active Active
- 2015-12-07 CN CN201580075401.6A patent/CN107429253B/zh not_active Expired - Fee Related
- 2015-12-07 IL IL290459A patent/IL290459B2/en unknown
- 2015-12-07 RU RU2017121826A patent/RU2727451C2/ru active
- 2015-12-07 EP EP15819937.2A patent/EP3227315B1/en not_active Not-in-force
- 2015-12-07 MX MX2017007250A patent/MX384964B/es unknown
- 2015-12-07 CA CA2969704A patent/CA2969704C/en active Active
- 2015-12-07 BR BR112017011893-9A patent/BR112017011893A2/pt not_active Application Discontinuation
- 2015-12-07 WO PCT/US2015/064303 patent/WO2016090369A1/en not_active Ceased
- 2015-12-07 CN CN202111214014.XA patent/CN114085856A/zh active Pending
- 2015-12-07 EP EP22208847.8A patent/EP4219530A1/en not_active Withdrawn
- 2015-12-07 KR KR1020177018597A patent/KR102558502B1/ko active Active
- 2015-12-07 JP JP2017529682A patent/JP7098325B2/ja active Active
-
2017
- 2017-06-04 IL IL252645A patent/IL252645B/en active IP Right Grant
- 2017-06-05 MX MX2021008498A patent/MX2021008498A/es unknown
-
2020
- 2020-08-13 US US16/992,361 patent/US11730797B2/en active Active
-
2021
- 2021-01-11 AU AU2021200122A patent/AU2021200122B2/en not_active Ceased
- 2021-02-16 IL IL280917A patent/IL280917B/en unknown
-
2022
- 2022-01-07 JP JP2022001433A patent/JP7252379B2/ja active Active
-
2023
- 2023-07-10 US US18/349,678 patent/US12497440B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022051744A5 (enExample) | ||
| JP2022017333A5 (enExample) | ||
| US20220170097A1 (en) | Car t cell transcriptional atlas | |
| US12152077B1 (en) | Immunotherapy targeting tumor neoantigenic peptides | |
| JP2019511236A5 (enExample) | ||
| EP3847195B1 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| RU2016143389A (ru) | Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом | |
| JP2018535668A5 (enExample) | ||
| IL292650B1 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| CN109415687A (zh) | 嵌合抗原受体t细胞组合物 | |
| JP2017537627A5 (enExample) | ||
| EP3870600A1 (en) | Er tunable protein regulation | |
| FI2884999T4 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| JP2019509029A5 (enExample) | ||
| CA3001859A1 (en) | Compositions and methods for inhibition of lineage specific antigens | |
| JP2021500889A5 (enExample) | ||
| JP2019525914A5 (enExample) | ||
| CN109328230A (zh) | 嵌合同种异体抗原受体t细胞的组合物和方法 | |
| JP2018516082A5 (enExample) | ||
| JP2016514457A5 (enExample) | ||
| AU2022232196A1 (en) | Transmembrane neoantigenic peptides | |
| CN111601882A (zh) | 工程化的免疫细胞的应用和生产 | |
| US20250122471A1 (en) | Engineered antigen presenting cells and uses thereof | |
| JP2015524413A5 (enExample) | ||
| JP2022512538A (ja) | Ｅｂｖ関連がんの処置のための抗ｌｍｐ２ ｔｃｒ－ｔ細胞療法 |